期刊中心

The Lancet Oncology
(LANCET ONCOL) 《柳叶刀肿瘤学杂志》

网友评分
柳叶刀肿瘤学杂志
2015年影响因子
26.509
期刊介绍

《柳叶刀·肿瘤学》致力于成为发布最高质量临床肿瘤学研究与观点的兼具全球性、权威性和独立性的平台。它是目前肿瘤学领域影响力名列前茅的一份期刊,在所有科学期刊中也属于影响因子最高的0.5%。

《柳叶刀·肿瘤学》刊登:原创性研究论文、综述、个人观点、评论及新闻。这份期刊有严格的编辑与同行评议制度,从而保证了其内容具有科学价值和临床相关性。所有原创性研究可在投稿后8周内发表。

展开
推荐阅读
目录导读
Published 2013年9月,Volume 14,Issue 9

最新一期

Editorial

787
Cleaning our polluted skies
The Lancet Oncology

Comment

788
Air pollution: another cause of lung cancer
Takashi Yorifuji, Saori Kashima
789
Glioblastoma: bridging the gap with gene therapy
Thierry VandenDriessche, Marinee K Chuah
791
Dose-intensive cisplatin for hepatoblastoma: have you heard?
Muna Qayed, Howard M Katzenstein
792
Hyperthermia in paediatric germ-cell tumours
Thomas A Olson
794
Hormone receptors and ovarian cancer survival
Charlie Gourley
795
The long road to bladder sparing in muscle invasive cancer
Alejandro Martinez-Fernandez
797
Infertility in women after childhood cancer
Richard A Anderson
798
PARP inhibitors: pitfalls and promises
Jeffrey R Infante, Howard A Burris
800
Docetaxel: time to reassess combination strategies
Stéphane Oudard
801
Denosumab treatment of giant cell tumour of bone
Maurice Balke
802
The promise of innovation in radiation oncology?
Edward C Halperin

Correspondence

e337
Advanced supportive care for patients with cancer in Latin America
Marcio Soares, Jorge I F Sullah
e337
Cancer control in Chile
Lorena Báez Alcaíno, María Cristina Escobar Fritzsche,Lorna Luco Canales
e338
Cancer control in Chile – Authors' reply
Yanin Chávarri-Guerra, Richard Sullivan, Paul E Goss
e339
Palliative care in urban areas of China
Xing Li, Yan-Fang Xing, Zhan-Hong Chen, Min Dong,Xiang-Yuan Wu
e339
Effect of pigmentation on photodynamic therapy
Zoe Apalla, Aimilios Lallas, Eleni Sotiriou, Demetrios Ioannides
e340
Effect of pigmentation on photodynamic therapy – Authors' reply
Aimée Arits, Nicole W Kelleners-Smeets
e340
Pancreaticogastrostomy after pancreaticoduodenectomy?
Baki Topal, Steffen Fieuws

Corrections

e342
Correction to Lancet Oncol 2013; 14: 678
 

News

805
Dosimetric promise versus cost: critics question proton therapy
Bryant Furlow
806
2013 International Symposium on Supportive Care in Cancer
Andy McLarnon
807
Carcinogenicity of some drugs and herbal products
Yann Grosse, Dana Loomis, Béatrice Lauby-Secretan,Fatiha El Ghissassi, Véronique Bouvard, Lamia Benbrahim-Tallaa, Neela Guha, Robert Baan, Heidi Mattock, Kurt Straif, on behalf of the International Agency for Research on Cancer Monograph Working Group
e343
Combination chemotherapy for lung cancer patients
Holly Baker
e343
Targeting the B-cell signalling pathway in CLL and MCL
Sharan Prakash Sharma
e344
Artifacts marr the genetic signature of cancer
Jennifer Wong
e344
India urged to reverse dextropropoxyphene ban
Dinesh C Sharma
e345
Lenalidomide as first-line therapy for elderly CLL patients
Judith A Gilbert
e345
Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
Judith A Gilbert
e346
Cigarette packaging—EU progress, UK stalls
Michael Granovetter
e346
Arsenic trioxide combination improves survival in APL
Susan Mayor
e347
Virus-fighting protein causes mutations in cancers
Jennifer Wong
e347
Maintenance therapy improves survival of NSCLC patients
Michael Granovetter

Cancer and Society

Film
809
Father's Day
Stephanie Bartlett
Web
809
Understanding websites
Helen Budd
Books
810
The Quarry: away the Crow Road
Fiona Mitchell
Books
811
The End of Your Life Book Club
Jill Jouret
Theatre
812
Chimerica: the acrid scent of success
Cassie Coburn

Articles

813
Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)
Ole Raaschou-Nielsen, Zorana J Andersen, Rob Beelen,Evangelia Samoli, Massimo Stafoggia, Gudrun Weinmayr, Barbara Hoffmann, Paul Fischer, Mark J Nieuwenhuijsen, Bert Brunekreef, Wei W Xun, Klea Katsouyanni, Konstantina Dimakopoulou, Johan Sommar,Bertil Forsberg, Lars Modig, Anna Oudin, Bente Oftedal,Per E Schwarze, Per Nafstad, Ulf De Faire, Nancy L Pedersen, Claes-Göran Östenson, Laura Fratiglioni,Johanna Penell, Michal Korek, Göran Pershagen, Kirsten T Eriksen, Mette Sørensen, Anne Tjønneland, Thomas Ellermann, Marloes Eeftens, Petra H Peeters, Kees Meliefste, Meng Wang, Bas Bueno-de-Mesquita, Timothy J Key, Kees de Hoogh, Hans Concin, Gabriele Nagel,Alice Vilier, Sara Grioni, Vittorio Krogh, Ming-Yi Tsai,Fulvio Ricceri, Carlotta Sacerdote, Claudia Galassi,Enrica Migliore, Andrea Ranzi, Giulia Cesaroni, Chiara Badaloni, Francesco Forastiere, Ibon Tamayo, Pilar Amiano, Miren Dorronsoro, Antonia Trichopoulou,Christina Bamia, Paolo Vineis, Gerard Hoek
823
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Manfred Westphal, Seppo Ylä-Herttuala, John Martin,Peter Warnke, Philippe Menei, David Eckland, Judith Kinley, Richard Kay, Zvi Ram, for the ASPECT Study Group
834
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
József Zsiros, Laurence Brugieres, Penelope Brock,Derek Roebuck, Rudolf Maibach, Arthur Zimmermann,Margaret Childs, Daniele Pariente, Veronique Laithier,Jean-Bernard Otte, Sophie Branchereau, Daniel Aronson,Arun Rangaswami, Milind Ronghe, Michela Casanova,Michael Sullivan, Bruce Morland, Piotr Czauderna,Giorgio Perilongo, for the International Childhood Liver Tumours Strategy Group (SIOPEL)
843
Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study
Rüdiger Wessalowski, Dominik T Schneider, Oliver Mils,Verena Friemann, Olga Kyrillopoulou, Jörg Schaper,Christiane Matuschek, Karin Rothe, Ivo Leuschner,Reinhart Willers, Stefan Schönberger, Ulrich Göbel,Gabriele Calaminus, for the MAKEI study group
853
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Weiva Sieh, Martin Köbel, Teri A Longacre, David D Bowtell, Anna deFazio, Marc T Goodman, Estrid Høgdall,Suha Deen, Nicolas Wentzensen, Kirsten B Moysich,James D Brenton, Blaise A Clarke, Usha Menon, C Blake Gilks, Andre Kim, Jason Madore, Sian Fereday, Joshy George, Laura Galletta, Galina Lurie, Lynne R Wilkens,Michael E Carney, Pamela J Thompson, Rayna K Matsuno, Susanne Krüger Kjær, Allan Jensen, Claus Høgdall, Kimberly R Kalli, Brooke L Fridley, Gary L Keeney, Robert A Vierkant, Julie M Cunningham, Louise A Brinton, Hannah P Yang, Mark E Sherman, Montserrat García-Closas, Jolanta Lissowska, Kunle Odunsi, Carl Morrison, Shashikant Lele, Wiam Bshara, Lara Sucheston, Mercedes Jimenez-Linan, Kristy Driver,Jennifer Alsop, Marie Mack, Valerie McGuire, Joseph H Rothstein, Barry P Rosen, Marcus Q Bernardini, Helen Mackay, Amit Oza, Eva L Wozniak, Elizabeth Benjamin,Aleksandra Gentry-Maharaj, Simon A Gayther, Anna V Tinker, Leah M Prentice, Christine Chow, Michael S Anglesio, Sharon E Johnatty, Georgia Chenevix-Trench,Alice S Whittemore, Paul DP Pharoah, Ellen L Goode,David G Huntsman, Susan J Ramus
863
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
Timur Mitin, Daniel Hunt, William U Shipley, Donald S Kaufman, Robert Uzzo, Chin-Lee Wu, Mark K Buyyounouski, Howard Sandler, Anthony L Zietman
873
Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort
Sara E Barton, Julie S Najita, Elizabeth S Ginsburg,Wendy M Leisenring, Marilyn Stovall, Rita E Weathers,Charles A Sklar, Leslie L Robison, Lisa Diller
882
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster,Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter,Robert Iannone, Stan B Kaye, Johann S de Bono, Robert M Wenham
893
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I Quinn, Catherine M Tangen, Maha Hussain,Primo N Lara, Amir Goldkorn, Carol M Moinpour, Mark G Garzotto, Philip C Mack, Michael A Carducci, J Paul Monk, Przemyslaw W Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Celestia S Higano, Nicholas J Vogelzang, Ian M Thompson
901
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
Sant Chawla, Robert Henshaw, Leanne Seeger, Edwin Choy, Jean-Yves Blay, Stefano Ferrari, Judith Kroep,Robert Grimer, Peter Reichardt, Piotr Rutkowski, Scott Schuetze, Keith Skubitz, Arthur Staddon, David Thomas,Yi Qian, Ira Jacobs

Review

e348
Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery
John R Benson, Gordon C Wishart
e358
Inhibition of HSP90 molecular chaperones: moving into the clinic
Rocio Garcia-Carbonero, Amancio Carnero, Luis Paz-Ares
e370
Molecular neuro-oncology in clinical practice: a new horizon
Michael Weller, Stefan M Pfister, Wolfgang Wick,Monika E Hegi, Guido Reifenberger, Roger Stupp
e380
Prevention and management of treatment-induced pharyngo-oesophageal stricture
Eitan Prisman, Brett A Miles, Eric M Genden
发表评论网友评论(1)
  • 2015-03-09 00:25  发表袁正平   陕西华县铁道部第一工程局中心医院  骨科

    The Tumor is Embryo of the Organization ———“The Organization Gamete ”Fusion of Tumor formation hypothesis Yuan ZHeng-ping (1) Yang Ding-qiao (2) The Chinese Railway Constructs the First Construction Bureau Hua Xian Central Hospital Orthopedics Abstract: The occurrence of tumor is a biological problem. From the point of view of biological evolution, tumor is animal kingdom has degradation of androgyny reproductive mode in human body reflect, belongs to the low sexual reproduction, the tumor is low human embryo is a kind of organization embryo. From the point of view of cells to carry on the analysis, the somatic cell by meiosis of haploid cells, can be named "The organization gamete", in the human body chromosome have differences between the two "The organization gamete" phase fusion produce tumor cells,the tumor cell growth growth forms the tumor . The tumor is organization's embryo. Key words:  tumor.  occurring mechanism .  biological evolution。 sexual  reproduction .hermaphrodite 。haploid cell.   (1) Doctor in charge; The Chinese railway constructs the first construction bureau Hua Xian central hospital orthopedics (rtirement) .  SHanxi  Weinan Huaxian     714100 yuan.zhp@163.com (2)Thelibrarians.;  Xi'an  Jiaotong  university  medical  school  library   Shanxi  Xi`an   710061   


审稿周期: 投稿难度:
发表评论